tiprankstipranks
Trending News
More News >
Insulet (PODD)
NASDAQ:PODD
Advertisement

Insulet (PODD) AI Stock Analysis

Compare
940 Followers

Top Page

PODD

Insulet

(NASDAQ:PODD)

Rating:76Outperform
Price Target:
$370.00
▲(7.71% Upside)
Insulet Corporation's strong financial performance and positive earnings call sentiment are the primary drivers of its stock score. The company's robust revenue growth and improved leverage position, along with raised guidance, contribute significantly to its attractiveness. However, the high valuation and potential short-term overbought condition slightly temper the overall score.
Positive Factors
Financial Performance
PODD reported a +6% sales beat driven by strong execution both in the US and OUS, with raised FY25 guidance implying ~MSD % upside to 2H25 consensus.
Growth Potential
Insulet is considered one of the best-positioned companies in the diabetes MedTech sector, with favorable growth catalysts like strong international momentum and increasing profitability.
Market Position
Insulet had its highest quarter of competitive switches, indicating a successful strategy in attracting customers from competitors.
Negative Factors
Investor Concerns
Investors are still concerned about longer-term adjusted OMs as management would not commit to continued expansion.
Management Guidance
Management raised its total revenue and Omnipod (US and OUS) revenue guidance ranges after Q2, all of which were reported well ahead of pre-print estimates.

Insulet (PODD) vs. SPDR S&P 500 ETF (SPY)

Insulet Business Overview & Revenue Model

Company DescriptionInsulet Corporation is a medical device company that specializes in the development and manufacturing of innovative insulin delivery systems, primarily for people with diabetes. The company is best known for its Omnipod Insulin Management System, which offers a tubeless, wearable insulin pump designed to improve the quality of life for individuals managing diabetes. Insulet operates in the healthcare sector, focusing on diabetes management and has expanded its product offerings to include advanced technology that integrates with continuous glucose monitoring systems.
How the Company Makes MoneyInsulet generates revenue primarily through the sale of its Omnipod Insulin Management Systems and the related consumable products, such as insulin cartridges and infusion sets. The company has a subscription-based model for the consumables, which provides a recurring revenue stream as patients require ongoing supplies for their insulin delivery. Additionally, partnerships with healthcare providers and payers enhance its revenue model, as Insulet collaborates with insurance companies to ensure coverage for its products, thereby increasing accessibility for users. The company also invests in research and development to enhance its products, potentially leading to new revenue opportunities through innovation and improved technology integration with diabetes management solutions.

Insulet Key Performance Indicators (KPIs)

Any
Any
Revenue by Segment
Revenue by Segment
Chart Insights
Data provided by:Main Street Data

Insulet Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong revenue growth, particularly in international markets, and significant progress in expanding the Type 2 diabetes market. While there were some challenges with inventory charges and potential future impacts from Medicare changes, the company's overall performance and raised guidance indicate a positive outlook.
Q2-2025 Updates
Positive Updates
Record Revenue Growth
Insulet Corporation reported $649 million in revenue for Q2 2025, marking a 31% increase from the previous year. This is the first time the company has surpassed the $600 million mark.
Strong International Growth
International revenue grew by 38.8%, driven by demand for Omnipod 5 and customer base growth, particularly in the U.K., Germany, and France.
Increased Prescriber Base
The number of healthcare providers prescribing Omnipod 5 in the U.S. grew by approximately 20% from the previous year, reaching over 25,000.
Full-Year Guidance Raised
Insulet raised the full-year guidance for revenue growth and adjusted operating margin, marking the tenth consecutive year of 20% or more growth on a constant currency basis.
Expansion of Type 2 Diabetes Market
Type 2 diabetes new customer starts accelerated, with over 30% of U.S. new customer starts being Type 2. The Omnipod 5 showed significant improvements in clinical outcomes for Type 2 patients.
Negative Updates
Inventory-Related Charges
The company incurred approximately $10 million in inventory-related charges, including write-offs of legacy components.
Potential Impact of Medicare Changes
The recent Medicare proposal around competitive bidding could impact the industry, although Insulet believes its products under Medicare Part D are not eligible for competitive bidding.
Company Guidance
During Insulet Corporation's second quarter earnings call for 2025, the company reported a 31% year-over-year revenue growth, reaching $649 million, and announced surpassing the $600 million revenue mark for the first time. The U.S. revenue grew 28.7%, with international revenue experiencing a 38.8% increase. The company highlighted strong performance in its Omnipod 5 system, which contributed to the increase in new customer starts, especially in type 2 diabetes. Insulet raised its full-year guidance, predicting a total Omnipod revenue growth of 25% to 28% and a total company revenue growth of 24% to 27%. The firm also plans to continue expanding its presence internationally and enhancing its product innovation, including sensor integration. The adjusted operating margin for the quarter was 17.8%, with adjusted EBITDA at 24.3%. Gross margin was 69.7%, and the full-year gross margin is expected to be approximately 71%. The company is looking forward to further growth and innovation, as well as its upcoming Investor Day on November 20, 2025.

Insulet Financial Statement Overview

Summary
Insulet's financial performance is robust, with strong revenue growth and profitability metrics. The company has improved its leverage position and continues to generate healthy cash flows. While there is a slight decline in net profit margin, the overall financial health remains strong, positioning the company well in the medical devices industry.
Income Statement
85
Very Positive
Insulet has demonstrated strong revenue growth with a 7.3% increase in TTM, supported by a robust gross profit margin of 70.7%. The net profit margin has slightly decreased to 10% from the previous annual report's 20.2%, indicating some pressure on profitability. However, the EBIT and EBITDA margins remain healthy, reflecting efficient operations.
Balance Sheet
75
Positive
The company's debt-to-equity ratio has improved to 0.96 in TTM, showing reduced leverage compared to previous periods. Return on equity is strong at 18.4%, indicating effective use of equity to generate profits. The equity ratio stands at 42.2%, suggesting a balanced capital structure with a solid equity base.
Cash Flow
80
Positive
Insulet's free cash flow growth is impressive at 35% in TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.50, showing moderate cash conversion efficiency. The free cash flow to net income ratio of 0.78 suggests a healthy cash flow relative to net income.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.36B2.07B1.70B1.31B1.10B904.40M
Gross Profit1.67B1.45B1.16B805.60M752.10M582.30M
EBITDA407.30M423.70M323.60M109.50M139.60M113.20M
Net Income236.10M418.30M206.30M4.60M16.80M6.80M
Balance Sheet
Total Assets3.47B3.09B2.59B2.25B2.05B1.87B
Cash, Cash Equivalents and Short-Term Investments1.12B953.40M704.20M674.70M791.60M947.60M
Total Debt1.42B1.42B1.45B1.43B1.29B1.08B
Total Liabilities2.01B1.88B1.86B1.77B1.49B1.27B
Stockholders Equity1.46B1.21B732.70M476.40M556.30M603.60M
Cash Flow
Free Cash Flow392.60M305.40M70.10M-38.30M-190.80M-82.50M
Operating Cash Flow506.50M430.30M145.70M119.00M-68.10M84.00M
Investing Cash Flow-136.20M-146.20M-119.40M-191.10M-82.70M14.00M
Financing Cash Flow-78.90M-28.10M-13.60M-40.30M40.70M605.50M

Insulet Technical Analysis

Technical Analysis Sentiment
Positive
Last Price343.53
Price Trends
50DMA
305.64
Positive
100DMA
298.19
Positive
200DMA
283.07
Positive
Market Momentum
MACD
11.66
Negative
RSI
73.14
Negative
STOCH
81.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Positive. The current price of 343.53 is above the 20-day moving average (MA) of 322.57, above the 50-day MA of 305.64, and above the 200-day MA of 283.07, indicating a bullish trend. The MACD of 11.66 indicates Negative momentum. The RSI at 73.14 is Negative, neither overbought nor oversold. The STOCH value of 81.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PODD.

Insulet Risk Analysis

Insulet disclosed 39 risk factors in its most recent earnings report. Insulet reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Insulet Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$24.14B36.699.73%0.94%2.47%63.68%
76
Outperform
$23.93B104.9719.18%25.99%-40.46%
74
Outperform
$21.02B25.576.52%0.91%4.11%-14.43%
68
Neutral
$29.54B52.0222.83%9.30%-14.95%
56
Neutral
$26.11B-7.10%3.27%-0.76%-55.03%
51
Neutral
$7.86B-0.33-41.57%2.23%23.26%-2.03%
49
Neutral
$845.29M-111.91%25.84%-47.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
PODD
Insulet
343.53
131.02
61.65%
DXCM
Dexcom
74.30
4.48
6.42%
PHG
Koninklijke Philips
27.06
-1.84
-6.37%
STE
Steris
242.02
3.99
1.68%
ZBH
Zimmer Biomet Holdings
105.01
-8.42
-7.42%
TNDM
Tandem Diabetes Care
12.35
-28.77
-69.97%

Insulet Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Insulet Issues Redemption Notice for Convertible Notes
Neutral
Jun 9, 2025

On June 6, 2025, Insulet Corporation amended its Credit Agreement to refinance $481.25 million in term loans, reducing the interest rate margin and maintaining similar terms to the previous loans. Additionally, Insulet issued a redemption notice on June 9, 2025, for its outstanding Convertible Senior Notes due 2026, with plans to redeem them by August 20, 2025, potentially impacting stock transactions as hedge positions are unwound.

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Insulet Corporation Holds 2025 Annual Stockholders Meeting
Neutral
May 28, 2025

Insulet Corporation held its 2025 Annual Meeting of Stockholders on May 22, 2025, where shareholders elected three Class III directors, approved executive compensation, and ratified the appointment of Grant Thornton LLP as the independent public accounting firm for the fiscal year ending December 31, 2025. Additionally, the Insulet Corporation 2025 Stock Option and Incentive Plan was approved, indicating continued shareholder support for the company’s strategic initiatives and governance practices.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 22, 2025